Lipoprotein(a) and Long-Term Recurrent Infarction After an Acute Myocardial Infarction
- PMID: 37858663
- DOI: 10.1016/j.amjcard.2023.10.028
Lipoprotein(a) and Long-Term Recurrent Infarction After an Acute Myocardial Infarction
Abstract
Lipoprotein(a) (Lp[a]) is an emerging risk factor for incident ischemic heart disease. However, its role in risk stratification in in-hospital survivors to an index acute myocardial infarction (AMI) is scarcer, especially for predicting the risk of long-term recurrent AMI. We aimed to assess the relation between Lp(a) and very long-term recurrent AMI after an index episode of AMI. It is a retrospective analysis that included 1,223 consecutive patients with an AMI discharged from October 2000 to June 2003 in a single-teaching center. Lp(a) was assessed during index admission in all cases. The relation between Lp(a) at discharge and total recurrent AMI was evaluated through negative binomial regression. The mean age of the patients was 67.0 ± 12.3 years, 379 (31.0%) were women, and 394 (32.2%) were diabetic. The index event was more frequently non-ST-segment elevation myocardial infarction (66.0%). The median Lp(a) was 28.8 (11.8 to 63.4) mg/100 ml. During a median follow-up of 9.9 (4.6 to 15.5) years, 813 (66.6%) deaths and 1,205 AMI in 532 patients (43.5%) occurred. Lp(a) values were not associated with an increased risk of long-term all-cause mortality (p = 0.934). However, they were positively and nonlinearly associated with an increased risk of total long-term reinfarction (p = 0.016). In the subgroup analysis, there was no evidence of a differential effect for the most prevalent subgroups. In conclusion, after an AMI, elevated Lp(a) values assessed during hospitalization were associated with an increased risk of recurrent reinfarction in the very long term. Further prospective studies are warranted to evaluate their clinical implications.
Keywords: acute myocardial infarction; lipoprotein (a); mortality; recurrent myocardial infarction.
Copyright © 2023 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest Dr. Miñana received honoraria for lectures from Abbott and Teleflex. Alberto Cordero received lecture honoraria from AstraZeneca, Amgen, Bristol-Myers Squibb, Ferrer, Boehringer Ingelheim (Ingelheim, Germany), Merck Sharp & Dohme, Daiichi Sankyo, Novartis (Eli Lilly), Novo Nordisk, Sanofi, and Amarin and consulting fees from AstraZeneca, Ferrer, Sanofi, Amgen (Bristol), Novartis, Novo Nordisk, and Amarin. Dr. Fernández-Cisnal received honoraria for lectures from Abbott. Dr. Valero received honoraria for lectures from Abbott. Dr. Llergo received lecture honoraria from AstraZeneca, Bayer, Boehringer Ingelheim, Pfizer-BMS, Rovi, Eli Lilly, Novartis, and Vifor and consulting fees from AstraZeneca, Boehringer Ingelheim, and Novartis. Rosa Fernández-Olmo received honoraria for lectures from AstraZeneca, Sanofi, Novartis, Rovi, Amarin, and Amgen, and consulting fees from AstraZeneca, Sanofi, Organón, and Novartis. Dr. Castro received honoraria for lectures and consulting from Novartis, Amgen, Boehringer Ingelheim, Astra Zeneca, Novonordisk, Servier, Organón, and Daychii-Sankyo. Dr. Sanchis received honoraria for lectures from Abbott. Dr. Núñez received honoraria for lectures and consulting from Alleviant, AstraZeneca, Boehringer Ingelheim, Bayer, Cytokinetics, Pfizer (New York, New York), Novartis, NovoNordisk, Rovi, and Vifor Pharma. The remaining authors have no competing interest to declare.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
